Company intelligence / Profile preview

Velicept Therapeutics

Wayne, Pennsylvania, United Statesbiospace.com ↗

Ownership: Private
Employees: ~3000
Development stage: Phase 2

Overview

Solabegron demonstrated significant improvement in Phase II studies for OAB compared to placebo, with reduction in wet episodes and daily voids. In IBS studies, it showed significant reduction in pain and a trend for improved quality of life. Both studies indicated a tolerability profile similar to placebo[4].

Therapeutic areas: GastroenterologyUrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Solabegron

Beyond the preview

Go deeper on Velicept Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Velicept Therapeutics.

Explore the full profile